Compare ORKA & AN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORKA | AN |
|---|---|---|
| Founded | 2004 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.9B |
| IPO Year | 1997 | 1995 |
| Metric | ORKA | AN |
|---|---|---|
| Price | $94.55 | $169.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | $92.50 | ★ $244.33 |
| AVG Volume (30 Days) | ★ 737.6K | 509.7K |
| Earning Date | 05-13-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.71 |
| EPS | N/A | ★ 11.26 |
| Revenue | N/A | ★ $27,631,400,000.00 |
| Revenue This Year | N/A | $4.32 |
| Revenue Next Year | N/A | $2.89 |
| P/E Ratio | ★ N/A | $14.99 |
| Revenue Growth | N/A | ★ 3.24 |
| 52 Week Low | $14.89 | $165.14 |
| 52 Week High | $115.52 | $235.81 |
| Indicator | ORKA | AN |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 25.87 |
| Support Level | $83.25 | N/A |
| Resistance Level | $97.02 | $213.50 |
| Average True Range (ATR) | 4.53 | 7.89 |
| MACD | -0.01 | -4.24 |
| Stochastic Oscillator | 53.22 | 12.94 |
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
AutoNation is the second-largest automotive dealer in the United States, with 2025 revenue of $27.6 billion and over 245 dealerships, plus 52 collision centers. The firm also has 24 AutoNation USA used-vehicle stores, a captive lender, four auction sites, and three parts distributors across 20 states primarily in Sunbelt metropolitan areas. New-vehicle sales account for nearly half of revenue; the company also sells used vehicles, parts, and repair services as well as auto financing. The company (formerly Republic Industries) divested its waste management unit (Republic Services) in 1999 and its car rental businesses (ANC Rental) in 2000. Wayne Huizenga founded the company in the 1990s to bring the rollup acquisition strategy to auto retailing, which proved to be a smart move.